Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 30Endocrine 30CNS 8Gastrointestinal 7Thoracic 6Genitourinary 4Gynecologic 3Breast 3Sarcoma 2Dermatologic 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1NET 1

Conditions

Multiple Myeloma 1663Neoplasms, Plasma Cell 415Lymphoma, Non-Hodgkin 311Lymphoma 283Hodgkin Disease 281Leukemia, Lymphocytic, Chronic, B-Cell 274Precursor Cell Lymphoblastic Leukemia-Lymphoma 246Leukemia, Myeloid, Acute 223Leukemia 220Lymphoma, Mantle-Cell 196Lymphoma, Large B-Cell, Diffuse 196Lymphoma, Follicular 196Myelodysplastic Syndromes 194Recurrence 185Lymphoma, B-Cell, Marginal Zone 178Burkitt Lymphoma 172Lymphoma, Large-Cell, Immunoblastic 161Myeloproliferative Disorders 146Leukemia, Myeloid, Chronic-Phase 134Leukemia, Myeloid, Accelerated Phase 122Primary Myelofibrosis 121Immunoglobulin Light-chain Amyloidosis 120Waldenstrom Macroglobulinemia 119Lymphoma, T-Cell, Cutaneous 119Blast Crisis 114Leukemia, Myelomonocytic, Chronic 105Sezary Syndrome 100Mycosis Fungoides 100Neoplasms 97Leukemia, Hairy Cell 95

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thyroid Carcinoma, Anaplastic × Plasma cell × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡